News about Fosun International Limited (FOSUY) covers a broad range of topics reflecting its activities as a global innovation-driven consumer group. Company announcements and media releases describe developments across pharmaceuticals and healthcare, cultural tourism and consumption, financial services, and insurance, as well as updates on its innovation and globalization strategy.
Investors and observers can find news on Fosun’s pharmaceutical and healthcare initiatives, including progress in innovative drugs, medical devices, and healthcare services under entities such as Fosun Pharma and Henlius. Releases highlight clinical and regulatory milestones, new therapeutic indications, and the use of artificial intelligence in areas such as drug development decision-making and clinical trial prediction.
Coverage also includes cultural tourism and consumption news, such as performance and expansion of Club Med resorts under Fosun Tourism Group, cultural events, and consumer-focused projects. In financial services and insurance, news items discuss developments at Fosun Insurance Portugal (Fidelidade), asset servicing activities in Europe, and strategic portfolio adjustments, including asset sales and retained businesses.
Another important theme in Fosun-related news is ESG and sustainability. Articles describe its ESG ratings, inclusion in sustainability indices and yearbooks, climate disclosure practices, and social responsibility programs such as the Rural Doctors Program and contributions to global malaria treatment. Governance and award recognitions, including honors from organizations like Corporate Governance Asia, also feature prominently.
For those following FOSUY, this news stream provides insight into how Fosun advances its stated strategy of "Innovation + Globalization", how its core subsidiaries perform, and how it integrates ESG considerations into its operations. Regularly reviewing these updates can help readers understand the group’s evolving business focus and corporate priorities.
Fosun International (FOSUF) received the ESG & Corporate Sustainability Excellence Award at Hong Kong Economic Journal’s sustainability awards ceremony.
Its MSCI ESG rating has been upgraded to AAA, and its Hang Seng Sustainability Rating rose from AA- to AA+. Fosun was also named among the Top 1% in the S&P Global Sustainability Yearbook (China Edition) 2026 for the third consecutive year. The company aims to peak carbon emissions by 2028 and achieve carbon neutrality by 2050. In April 2026, it released its fourth Climate Information Disclosures Report, aligned with TCFD recommendations and IFRS S2 climate disclosure requirements.
Fosun (FOSUF) returned to the China International Import Expo, showcasing healthcare products with overseas member companies and global partners. Intuitive Surgical presented da Vinci 5 in China for the first time. Fosun plans to sign partnership agreements during the expo.
Fosun Pharma's disclosed regulatory milestones include China approval of injectable Akynzeo in 2026 and WANTILE's China approval and national reimbursement inclusion in 2025. The da Vinci SP surgical system entered China's special review procedure for innovative medical devices. HANSIZHUANG is available in more than 50 countries and regions, while HANQUYOU has marketing approval in more than 50. FUMAINING received Breakthrough Therapy Designation in Saudi Arabia; the company expects this to accelerate approval and commercialization there.
Fosun International (FOSUF, FOSUY) outlined its global pharmaceutical expansion strategy as Co-CEO Chen Qiyu addressed a Shanghai conference on October 20.
In the first half of 2026, Fosun Pharma's innovative-drug revenue rose 13.84% year-on-year to RMB4.911 billion, accounting for 33.35% of pharmaceutical business revenue. Total R&D investment increased 25.66% to RMB3.247 billion; innovative-drug R&D investment rose 48.38% to RMB2.650 billion.
Henlius has 10 products approved in over 60 countries and regions. Its HLX43 cancer treatment is being evaluated in more than ten clinical studies, with more than 1,500 patients enrolled worldwide. Fosun Pharma completed an upgrade of its PharmAID pharmaceutical intelligence platform, and two AI-assisted molecules have reached the preclinical candidate stage. The company aims to become a multinational innovative-drug company rooted in China, using global collaboration to expand access.
Fosun International (FOSUF, FOSUY) won five awards at The Asset Corporate Sustainability Leadership Awards 2026, including the Platinum Award. The main award represents an upgrade from Gold last year. The four category awards were Best in Disclosure & Transition, Best Initiative in Environmental Responsibility, Best Initiative in Social Responsibility, and Best Sustainability Team.
The environmental award recognized work addressing climate change and biodiversity, including the Sea Turtle Shelter at Atlantis Sanya. The social responsibility award recognized the Rural Doctors program and its AI Rural Doctor Assistant. Fosun International also reported an MSCI environmental, social and governance rating upgrade to AAA and a Hang Seng Sustainability Rating upgrade from AA- to AA+. In 2026, it released its fourth Climate Information Disclosures Report.
ClubMed Lifestyle Group (FOSUF) has joined the World Travel & Tourism Council as a Global Member, advancing its worldwide resort expansion.
The subsidiary of Fosun International operates premium all-inclusive resorts under the Club Med brand, which by 2025 turnover is described as the world's largest all-inclusive resort brand. Club Med currently runs 69 resorts in over 40 countries and regions across six continents, serving more than 1.5 million guests annually, and the group expects to reach about 85 resorts by 2030. Since late 2025, new resort projects have been signed in markets including China, Canada, Morocco, Brazil, the U.S. Virgin Islands, Indonesia and Italy.
In July, Club Med signed a strategic cooperation memorandum with Microsoft in Paris, focusing on AI-powered guest experiences, cloud-native transformation and operational modernisation, which the company says complements the WTTC recognition in supporting its growth path.
Fosun International (FOSUF) has had its Hang Seng Sustainability Rating raised from AA- to AA+ in the 2026 review effective 7 September 2026, its highest level to date.
The company was selected as a constituent of the Hang Seng Corporate Sustainability Benchmark Index for the seventh consecutive year and added to the Hang Seng ESG 50 Index. In 2026 it ranked in the top 10% of participating Hong Kong‑listed companies in Corporate Governance, Environment, Consumer Issues, and Community Involvement and Development. Fosun International’s MSCI ESG Rating has been upgraded to AAA under the latest 5.0 methodology, it was included in the S&P Global Sustainability Yearbook 2026 and ranked in the Top 1% in the China Edition for the third straight year, and it has remained in the FTSE4Good Index Series for five consecutive years.
Fosun International (OTC:FOSUF, FOSUY) held its 2026 interim results presentation in Hong Kong on 28 August, reporting first-half Group revenue of RMB86.96 billion and profit attributable to owners of the parent of RMB1.72 billion, a 160.3% year-on-year increase. Overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue.
According to Fosun International, four core businesses — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment — contributed 73.5% of Group revenue. Technology innovation investment in the first half of 2026 was RMB4.2 billion, up 16.7% year-on-year, mainly supporting pharmaceutical and healthcare R&D and a broader global innovation and operating ecosystem.
Fosun International (OTC:FOSUF) announced that its subsidiary ClubMed Lifestyle Group has submitted a listing application to the Main Board of the Hong Kong Stock Exchange, with BNP Paribas, HSBC and J.P. Morgan as joint sponsors. ClubMed Lifestyle Group operates premium all‑inclusive resorts led by the Club Med brand.
According to the listing application materials, ClubMed Lifestyle Group generated EUR 1.95 billion revenue in 2025, up from EUR 1.86 billion in 2023, and achieved adjusted EBITDA of EUR 390 million with a 20.2% margin. The group operates 69 resorts and expects to reach about 85 resorts worldwide by 2030. Upon completion of the proposed listing, proceeds are expected to be used to expand and upgrade its global resort network and to strengthen digital and AI capabilities.
Fosun International (OTC:FOSUF) announced that its subsidiary ClubMed Lifestyle Group has submitted a listing application to the Hong Kong Stock Exchange for a proposed separate listing on the Main Board. ClubMed Lifestyle Group operates premium all-inclusive resorts under the Club Med brand and related vacation concepts using an asset-light model.
Club Med currently runs 69 resorts worldwide and, by business volume in 2025, was the world's largest all-inclusive resort brand. Revenue grew from EUR 1.86 billion in 2023 to EUR 1.95 billion in 2025, while gross profit increased from EUR 540 million to EUR 590 million. Adjusted EBITDA reached EUR 390 million in 2025, with a margin of 20.2%. ClubMed Lifestyle Group expects to operate about 85 resorts by 2030. Proceeds from the proposed listing are planned mainly for global resort expansion, product upgrades, and digital and AI capabilities, with the remainder for capital structure optimisation and daily operations.
Fosun International (OTC:FOSUF, FOSUY) reported 1H2026 total revenue of RMB86.96 billion, broadly stable year-on-year, while profit attributable to owners surged 160.3% to RMB1.72 billion. Industrial operation profit reached RMB3.69 billion, up 17%, reflecting improved operational quality in core sectors including pharmaceuticals, insurance, and cultural tourism.
Overseas revenue rose 5.3% to RMB49.16 billion, accounting for 56.5% of Group revenue, and core subsidiaries generated RMB63.88 billion, or 73.5% of total. According to Fosun International, technology innovation investment grew 16.7% to RMB4.2 billion, while divestments of non-core assets exceeded RMB12.0 billion. As of 30 June 2026, cash, bank balances and term deposits were RMB61.214 billion, and the total debt to total capital ratio improved to 55.7%. The Group’s MSCI ESG rating was upgraded to AAA.